ArticleAnnals of clinical and translational neurology2026
FDG-PET Associations With Disease Severity and Outcomes in NMDA-Receptor IgG Autoimmune Encephalitis.
Article in Annals of clinical and translational neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPatients with N-methyl-D-aspartate (NMDA) receptor-immunoglobulin G (IgG) autoimmune encephalitis (NMDAR-IgG AE) demonstrate occipital lobe hypometabolism on baseline brain fluorodeoxyglucose-positron emission tomography (bFDG-PET). The goal of this study was to determine whether there is an association between bFDG-PET findings, disease severity, and clinical outcomes in these patients.
methodsThis retrospective analysis included adult patients with NMDAR-IgG AE who underwent bFDG-PET within 3 months of symptom onset. Qualitative and quantitative assessments of bFDG-PET findings were performed. Spearman's correlation analysis was used to evaluate potential associations between bFDG-PET findings and clinical severity at diagnosis and at 1 year using modified Rankin Scale (mRS) and Clinical Assessment Scale for Autoimmune Encephalitis (CASE) scores.
resultsSixteen patients (13 women, 3 men; median age, 29.0 years) were included in the analysis. The median time between symptom onset and bFDG-PET was 5 weeks (interquartile range: 3-8). All patients received immunosuppressive therapy. Qualitative and quantitative assessments demonstrated the highest correlation between occipital lobe hypometabolism and clinical severity at diagnosis (Quantitative: mRS: -0.65 [95% confidence interval (CI): -0.87, -0.22]; CASE: -0.68 [95% CI: -0.88, -0.28]). At 1 year (n = 12), quantitative baseline occipital lobe hypometabolism was correlated with higher mRS scores (-0.71 [95% CI: -0.91, -0.23]).
conclusionsIn patients with NMDAR-IgG AE, occipital lobe hypometabolism on baseline bFDG-PET is correlated with mRS and CASE scores at the time of diagnosis and mRS scores 1 year later, suggesting that bFDG-PET findings correlate with disease severity and longitudinal outcomes. However, studies with larger patient populations are needed to confirm these findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.